- Home
- DXYZ vs RAPT Comparison
DXYZ vs RAPT Comparison
Compare DXYZ & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | RAPT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.6M | 498.4M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | RAPT |
|---|---|---|
| Price | $30.29 | $36.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | N/A | ★ 494.8K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $5.67 |
| 52 Week High | N/A | $42.39 |
Technical Indicators
Market Signals| Indicator | DXYZ | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 62.08 |
| Support Level | $29.11 | $31.70 |
| Resistance Level | $33.62 | $37.75 |
| Average True Range (ATR) | 3.22 | 2.60 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 35.66 | 71.26 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.